Why I am bullish on Achillion Pharmaceuticals, Inc. (ACHN)
216
Achillion Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders in the United States. Its lead drug candidate includes ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria and C3 glomerulopathy.
Decide to enter a bullish trade at $1.63 after crossing above the EMA(10). This a very affordable stock but is also risky trade. Therefore using a trailing stop is a must on this trade..
---------------------------- This post is for general information purposes only. It is not investment advice or a solution to buy or sell securities.